Vistin Pharma ASA (LTS:0RAM) Policyholder Funds

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
75 GF Score
Price kr20.40
GF Value kr25.77
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Policyholder Funds?

Policyholder Funds only applies to insurance companies.

LTS:0RAM
75GF Score
Vistin Pharma ASA LTS:0RAM
Policyholder Funds is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.40 is trading 20.8% below its estimated GF Value™ of kr25.77. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Policyholder Funds:
  • GF Value™: kr25.77 vs. price of kr20.40 (20.8% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score

Get the complete analysis for LTS:0RAM

Policyholder Funds is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.40
Price
kr25.77
GF Value